Abeona Therapeutics (NASDAQ:ABEO) SVP Sells $33,416.50 in Stock

Posted by Brian Himes on Jun 12th, 2026

Abeona Therapeutics Inc. (NASDAQ:ABEO – Get Free Report) SVP Brendan O’malley sold 6,305 shares of Abeona Therapeutics stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $5.30, for a total transaction of $33,416.50. Following the sale, the senior vice president owned 440,003 shares of the company’s stock, valued at approximately $2,332,015.90. The trade was a 1.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abeona Therapeutics Price Performance

ABEO stock opened at $5.53 on Friday. The firm has a 50 day moving average of $5.42 and a 200-day moving average of $5.17. Abeona Therapeutics Inc. has a 12-month low of $4.00 and a 12-month high of $7.54. The company has a current ratio of 5.89, a quick ratio of 5.70 and a debt-to-equity ratio of 0.03. The company has a market cap of $315.15 million, a price-to-earnings ratio of 5.70 and a beta of 1.35.

Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. The company had revenue of $8.72 million for the quarter, compared to analyst estimates of $4.57 million. As a group, equities analysts expect that Abeona Therapeutics Inc. will post -0.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Royal Bank of Canada increased its stake in shares of Abeona Therapeutics by 49.6% during the 1st quarter. Royal Bank of Canada now owns 6,500 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 2,155 shares in the last quarter. Rangeley Capital LLC increased its stake in shares of Abeona Therapeutics by 4.2% during the 1st quarter. Rangeley Capital LLC now owns 60,000 shares of the biopharmaceutical company’s stock worth $269,000 after purchasing an additional 2,400 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Abeona Therapeutics by 38.6% during the 1st quarter. Renaissance Technologies LLC now owns 161,082 shares of the biopharmaceutical company’s stock worth $722,000 after purchasing an additional 44,882 shares in the last quarter. Sei Investments Co. increased its stake in shares of Abeona Therapeutics by 142.4% during the 1st quarter. Sei Investments Co. now owns 172,460 shares of the biopharmaceutical company’s stock worth $773,000 after purchasing an additional 101,307 shares in the last quarter. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Abeona Therapeutics during the 1st quarter worth approximately $154,000. 80.56% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on ABEO shares. Wall Street Zen upgraded shares of Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, June 1st. Oppenheimer reiterated an “outperform” rating on shares of Abeona Therapeutics in a research report on Monday, March 9th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a research report on Thursday, May 28th. Finally, Stifel Nicolaus set a $17.00 price objective on shares of Abeona Therapeutics in a research note on Tuesday, March 17th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $19.00.

Get Our Latest Stock Analysis on ABEO

Abeona Therapeutics Company Profile

(Get Free Report)

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.